Stepan Company — Q1 2024 Form 10-Q Summary
Reporting period: Three months ended March 31, 2024; comparative period is Q1 2023. The unaudited filing covers Stepan’s global specialty and intermediate chemicals business: Surfactants, Polymers and Specialty Products.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $551.4 million | $651.4 million | Down 15% |
| Gross profit | $70.3 million | $73.6 million | Down 4% |
| Gross margin | 12.7% | 11.3% | Up about 1.4 points |
| Operating income | $20.2 million | $21.1 million | Down 4% |
| Operating margin | 3.7% | 3.2% | Up about 0.4 points |
| Net income | $13.9 million | $16.1 million | Down 14% |
| Diluted EPS | $0.61 | $0.70 | Down 13% |
| Adjusted net income / diluted EPS | $14.7 million / $0.64 | $16.4 million / $0.71 | Down |
| EBITDA / adjusted EBITDA | $50.2 million / $51.2 million | $48.3 million / $48.7 million | Adjusted EBITDA up 5% |
Sales declined primarily because lower average selling prices, largely reflecting raw-material cost pass-throughs, reduced revenue by $115.5 million. Volume rose 1% and foreign-currency translation added $11.8 million to sales. The improvement in gross margin alongside lower gross profit reflects the substantially lower revenue base.
- Segments: Surfactants sales fell 16% and operating income fell 4%; Polymers sales fell 10% and operating income fell 16%; Specialty Products sales fell 33%, while operating income rose 69%, supported by stronger margins and volume in medium-chain triglycerides.
- Cash flow: Operating cash flow was $41.6 million, versus a $72.1 million use in Q1 2023. Capital spending was $30.2 million versus $92.2 million. Cash used in investing was $24.4 million; cash used in financing was $20.0 million.
- Liquidity and debt: Cash was $125.8 million at March 31, including $123.1 million held by non-U.S. subsidiaries. Total debt was $646.0 million; net debt was $520.2 million, down from $524.3 million at year-end 2023. The credit agreement had $152.8 million available, after $280.0 million of borrowings and $11.0 million of letters of credit. The company reported covenant compliance.
- Other metrics: Effective tax rate was 28.6%, compared with 18.9%. The quarterly dividend paid was $0.375 per share. Environmental and legal accruals were $20.8 million, at the low end of an estimated loss range of $20.8 million to $49.8 million.
Material changes and management commentary
Lower selling prices were the principal driver of reduced sales. Management cited lower raw-material costs, unfavorable product mix and competitive pressure, especially in Europe and Latin America. Surfactant demand was mixed: North American agricultural demand remained weak amid customer and channel destocking, while Latin American volume increased. Millsdale operational interruptions reduced North American Polymers performance, including a 43% decline in commodity phthalic anhydride volume. These interruptions also increased maintenance, tolling and wastewater costs. Pasadena alkoxylation facility pre-operating costs affected North American Surfactants.
Management expects gradual volume improvement, including recovery in rigid polyols demand and agricultural sales in the second half of 2024. It reiterated a target of $50 million in pre-tax savings from its cost-reduction program and expects full-year adjusted EBITDA growth and positive free cash flow. The company estimates 2024 capital expenditures of $120 million to $140 million, including completion of the Pasadena facility. Management expects cash from operations, available credit and cash on hand to fund planned needs.
Risks, contingencies and unusual items
- The company received a March 2024 EPA notice alleging air-regulation violations at its Millsdale facility; the notice did not specify whether penalties or operational remedies would be pursued. The outcome and financial effect are not yet estimable.
- Environmental matters remain uncertain. A Maywood consent decree was entered in February 2024; remediation costs at Maywood and other sites could differ materially from recorded estimates. A liability for potential natural-resource damages related to the Wilmington site was recorded in Q1.
- Management attributes the higher tax rate primarily to its intended bonus-depreciation election for the Pasadena facility, which is expected to limit use of the GILTI deduction and related foreign tax credits in 2024.
- Deferred-compensation and investment-value changes affected reported earnings. Other, net included $2.3 million of realized and unrealized investment gains, partly offset by deferred-compensation expense. Adjusted measures exclude selected items and are non-GAAP.
- Key broader risks include raw-material and energy cost or supply volatility, demand and competitive pressures, production disruptions, environmental regulation, foreign exchange, capital-project execution, litigation, and debt-covenant or capital-market risks.
Important facts for investors to verify
- Whether volumes, particularly agricultural and rigid-polyols demand, recover as management expects in the second half of 2024.
- Whether Millsdale operating performance improves and how the EPA matter, Maywood decree and Wilmington claims affect costs and cash flows.
- Progress, commissioning costs and timing for the Pasadena facility, alongside the $120 million to $140 million capital-spending outlook.
- Delivery of the $50 million cost-savings target, adjusted EBITDA growth and positive free cash flow; reconcile these non-GAAP measures to GAAP results.
- Tax-rate effects of the Pasadena depreciation election, and liquidity, debt maturities and covenant headroom as investment spending continues.